Effectiveness of daily use of brimonidine as antimydriatic agent.
Sandra
S
Brown
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000494:pharmacology; D000068438:Brimonidine Tartrate; D006801:Humans; D008027:Light; D010276:Parasympatholytics / Q000009:adverse effects / Q000494:pharmacology; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology*; D011680:Pupil / Q000187:drug effects* / Q000528:radiation effects; D011810:Quinoxalines / Q000009:adverse effects / Q000494:pharmacology*; D011812:Quinuclidines / Q000009:adverse effects / Q000494:pharmacology*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology*
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D010276:Parasympatholytics; D010879:Piperazines; D011810:Quinoxalines; D011812:Quinuclidines; D014230:Triazoles; C084650:aceclidine; D000068438:Brimonidine Tartrate; C035289:dapiprazole